Arrowhead Pharmaceuticals Inc - On February 10
On February 10, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2025 that ended...
226 Views
ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing
On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics...
282 Views
ARWR: PALISADE Phase 3 Results Published in NEJM
On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with...
362 Views
ARWR: Two Obesity Assets to Enter the Clinic in 2025
On August 8, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2024 that ended June...
319 Views
ARWR: Summer Webinar Series to Highlight Development Pipeline
On May 9, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2024 that ended March 31,...
316 Views